December 13, 2024
Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
December 10, 2024
Ocular Therapeutix™ to Present at the 43rd Annual J.P. Morgan Healthcare Conference
December 2, 2024
Ocular Therapeutix™ Announces More Than 300 Subjects Randomized in SOL-1
November 26, 2024
Ocular Therapeutix™ to Participate in December Investor and Scientific Conferences
November 14, 2024
Ocular Therapeutix™ Reports Third Quarter 2024 Results and Business Highlights
November 13, 2024
Ocular Therapeutix™ to Present at the Jefferies London Healthcare Conference and Ophthalmology Innovation Summit XIV
November 12, 2024
Ocular Therapeutix™ Appoints Namrata Saroj, OD, as Chief Business Officer
November 6, 2024
Ocular Therapeutix™ to Report Third Quarter 2024 Results on November 14, 2024
October 15, 2024
Ocular Therapeutix™ Announces Accelerated Timelines for SOL-1 Registrational Trial of AXPAXLI™ in Wet AMD
October 9, 2024
Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
October 9, 2024
Ocular Therapeutix™ to Present at October Ophthalmology Meetings
September 25, 2024
Ocular Therapeutix™ to Present at the UBS Virtual Ophthalmology Day 2024
September 12, 2024
Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
September 5, 2024
Ocular Therapeutix™ to Present at September Retina Meetings
September 4, 2024
Ocular Therapeutix™ to Present at Two Investor Conferences in September
August 9, 2024
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 7, 2024
Ocular Therapeutix™ Announces FDA Feedback That SOL-R Trial is Appropriate as a Registrational Study in Wet AMD
August 7, 2024
Ocular Therapeutix™ Reports Second Quarter 2024 Results
July 31, 2024
Ocular Therapeutix™ to Report Second Quarter 2024 Financial Results on August 7, 2024
July 30, 2024
Ocular Therapeutix™ Announces First Patients Enrolled in Phase 3 SOL-R Wet AMD Study
July 18, 2024
Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
July 10, 2024
Ocular Therapeutix™ Announces Late-Breaking Abstract of HELIOS Study to be Presented at 42nd ASRS Annual Scientific Meeting
July 8, 2024
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 13, 2024
Ocular Therapeutix™ Highlights Exceptional AXPAXLI™ SOL-1 Enrollment and Plans for Repeat Dosing Study (SOL-R) in wet AMD at Investor Day, Along with Positive 48-week Data from HELIOS NPDR Study
June 5, 2024
Ocular Therapeutix™ to Host Investor Day on June 13, 2024
June 4, 2024
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 7, 2024
Ocular Therapeutix™ Reports First Quarter 2024 Results
May 6, 2024
Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 6, 2024
Ocular Therapeutix™ to Present at Two Upcoming Investor Conferences
May 3, 2024
Ocular Therapeutix™ To Present at Two Ophthalmology Meetings, May 4-9, 2024
May 1, 2024
Ocular Therapeutix™ to Host Investor Day in New York City on Thursday, June 13, 2024
April 18, 2024
Ocular Therapeutix™ Announces Positive Topline Phase 1 Data for AXPAXLI™ in Diabetic Retinopathy
April 16, 2024
Ocular Therapeutix™ Strengthens Clinical Team with Appointment of Key Retinal Leaders
April 15, 2024
Ocular Therapeutix™ Executive Chairman Pravin U. Dugel, MD Becomes President and CEO Antony Mattessich is Stepping Down as President and CEO
April 9, 2024
Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Senior Vice President of Global Head of Biometrics
April 6, 2024
Ocular Therapeutix™ Announces Positive Phase 2 PAXTRAVA™ Glaucoma Data at the American Society of Cataract and Refractive Surgery 2024 Annual Meeting
March 26, 2024
Ocular Therapeutix™ To Present Data at the 2024 ASCRS Annual Meeting (American Society of Cataract and Refractive Surgery)
March 11, 2024
Ocular Therapeutix™ Reports Fourth Quarter and Full Year 2023 Results
March 5, 2024
Ocular Therapeutix™ to Release Fourth Quarter and Full Year 2023 Results on March 11, 2024
February 22, 2024
Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Executive Chairman and Chief Strategy Officer
February 22, 2024
Ocular Therapeutix, Inc. Announces $325.0 Million Private Placement
February 22, 2024
Ocular Therapeutix™ Announces Board of Directors and Leadership Updates
February 15, 2024
Ocular Therapeutix™ Appoints Steve Meyers to Chief Commercial Officer
February 13, 2024
Ocular Therapeutix™ Announces First Subjects Screened in Phase 3 Pivotal Clinical Trial of AXPAXLI™ in Wet AMD
January 25, 2024
Ocular Therapeutix™ Announces FDA Agreement to Amend Special Protocol Assessment (SPA) for Pivotal Clinical Trial of AXPAXLI™ in Wet AMD
